Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lisdexamfetamine.

Stephanie K A Blick1, Gillian M Keating

  • 1Wolters Kluwer Health/Adis, Auckland, New Zealand.

Paediatric Drugs
|April 5, 2007
PubMed
Summary
This summary is machine-generated.

Lisdexamfetamine, an attention-deficit hyperactivity disorder (ADHD) medication, offers improved ADHD symptom control in children. Its prodrug design suggests a lower abuse potential compared to traditional stimulants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Recent Advances in the Pharmacological Management of Pediatric Spondyloarthritis.

Paediatric drugs·2026
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatrics

Background:

  • Lisdexamfetamine is an FDA-approved prodrug for treating attention-deficit hyperactivity disorder (ADHD) in children aged 6-12.
  • It consists of dextroamphetamine covalently bonded to l-lysine, forming an inactive molecule until hydrolyzed in the body.

Purpose of the Study:

  • To evaluate the efficacy and safety of lisdexamfetamine in pediatric patients with ADHD.
  • To assess the abuse potential of lisdexamfetamine compared to dextroamphetamine in adults.

Main Methods:

  • Two randomized, placebo-controlled trials were conducted in children aged 6-12 with ADHD.
  • A pharmacodynamic study in adult stimulant abusers compared the 'likability' of lisdexamfetamine and dextroamphetamine.

Related Experiment Videos

Main Results:

  • Lisdexamfetamine demonstrated superior efficacy over placebo in improving ADHD symptoms in children.
  • In adults, lisdexamfetamine showed reduced 'likability' compared to dextroamphetamine, suggesting a lower abuse potential.
  • Adverse events were generally mild to moderate and consistent with amphetamine-class medications.

Conclusions:

  • Lisdexamfetamine is an effective treatment for ADHD in children, with a pharmacokinetic profile suggesting a reduced potential for abuse.
  • The prodrug mechanism of lisdexamfetamine allows for gradual release of dextroamphetamine, contributing to its therapeutic profile.